COPD is a major health problem with more than 140,000 deaths per year and yet there is a relative paucity of treatments that might modify the course of this disease. In part, this is due to the poor efficiency of animal models that require months of exposure to cigarette smoke. Moreover, there are no well validated small animal models of chronic mucus hypersecretion. Funding of core facilities that could both provide ...more »
How can we control environmental risks (smoking, obesity, activity levels)?
What are the factors that determine resistance to smoking-related heart and lung disease?
What are the common pathways amenable to intervention to prevent smoking related to heart and lung disease?
How can we reduce the burden of vascular disease by promoting healthy lifestyle including diet, exercise, and smoking cessation?
What barriers and facilitators modify the effectiveness of smoking cessation programs in patients with COPD?
What is the role of cellular senescence in age-related lung disease? Do environmental factors, including smoking, contribute to the pathogenesis of lung disease through their ability to induce premature senescence? Does the accumulation of senescent cells in distal organs contribute to age-related lung disease through systemic inflammation?
What knowledge about health behavior change can be leveraged to design innovative and effective strategies for behavior change among the most vulnerable individuals?
What is nicotine addiction in the absence of other materials? What cues are associated with smoking? We would like to see brain reward studies in special populations. We are also interested in understanding possible reduced harm in people who use e-cigarettes in cessation attempts, and understanding whether e-cigs are a gateway to other risky behaviors for young people who are experimenting.
What is the comparative effectiveness and cost effectiveness of counseling plus nicotine replacement vs. counseling plus bupropion vs. counseling plus varenicline on smoking cessation rates, patient-reported outcomes (symptom frequency, activities of daily living, quality of life, sleep quality, exacerbations), and COPD and non-COPD morbidity/mortality?
a. Enhance our understanding of the behavioral issues that lead to smoking addiction
b. Explore effective behavioral and pharmacological and non-pharmacological mechanisms to reverse smoking addiction
We are concerned about access to smoking cessation programs in populations that are hard to reach (rural) and who have other challenges (underserved/marginalized populations including people with serious mental illness). What kind of computer-based or mobile health technologies can assist these groups?
What can be done to prevent the development of COPD in individuals at increased risk. Quitting smoking before the development of COPD can prevent COPD development. What can be done to prevent COPD for individuals with other identified ris factors